Convergence of Computational Protein Design, Directed Evolution, and Genome Engineering in Pharmaceutical Biocatalysis: Progress, Challenges, and Future Directions
Center of Engineering Sciences · 30.10.2026 · 1 (1) · 32-44
DOI: 10.65591/ces-187-2026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Center of Engineering Sciences, online erschienen am 30.10.2026. Verfasst von Mubaraq Damilare Yussuf und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Growing regulatory scrutiny, heightened environmental accountability, and the structural complexity of contemporary drug molecules have collectively repositioned biocatalysis from a supplementary laboratory technique to an indispensable pillar of pharmaceutical manufacturing. Active pharmaceutical ingredients (APIs) are the drug substances whose manufacture is the principal focus of pharmaceutical biocatalysis. Enzymes offer intrinsic advantages in chemo-, regio-, and stereoselectivity under physiologically benign conditions; however, their native catalytic parameters frequently fall short of the efficiency and robustness demanded by industrial active pharmaceutical ingredient (API) synthesis. The past decade has witnessed the emergence of a convergent engineering paradigm that unifies computational protein design, directed evolution, and clustered regularly interspaced short palindromic repeats–CRISPR-associated (CRISPR-Cas) genome engineering into an integrated workflow capable of rapidly generating purpose-built biocatalysts. Computational methods encompassing molecular dynamics simulation, energy landscape modelling, and transformer-based protein language models compress experimental search spaces by prospectively identifying functional mutations. Directed evolution subsequently subjects these computational predictions to iterative empirical refinement under conditions that reflect realistic industrial constraints. Genome engineering operating at the host-cell level then configures microbial expression systems for maximal enzyme yield, cofactor sufficiency, and metabolic coherence. This review critically appraises the mechanistic basis, demonstrated accomplishments, and outstanding technical barriers of each constituent approach before examining the synergistic advantages that emerge from their convergent deployment. Representative pharmaceutical applications including asymmetric reductive amination, stereoselective ketoreduction, and multi-enzyme cascade synthesis are evaluated in the context of green chemistry metrics. Emerging directions encompassing autonomous self-driving laboratories, generative AI protein design, and sustainability-oriented bioprocess engineering are also addressed.
Zitieren
APA
Yussuf, M. D., & Olawuyi, M. D. (2026). Convergence of Computational Protein Design, Directed Evolution, and Genome Engineering in Pharmaceutical Biocatalysis: Progress, Challenges, and Future Directions. Center of Engineering Sciences, 1(1), 32-44. https://doi.org/10.65591/ces-187-2026
Vancouver
Yussuf MD, Olawuyi MD. Convergence of Computational Protein Design, Directed Evolution, and Genome Engineering in Pharmaceutical Biocatalysis: Progress, Challenges, and Future Directions. Center of Engineering Sciences. 2026;1(1):32-44. doi:10.65591/ces-187-2026
BibTeX
@article{Yussuf2026,
author = {Yussuf, Mubaraq Damilare and Olawuyi, Mariam Damilola},
title = {Convergence of Computational Protein Design, Directed Evolution, and Genome Engineering in Pharmaceutical Biocatalysis: Progress, Challenges, and Future Directions},
journal = {Center of Engineering Sciences},
year = {2026},
volume = {1},
number = {1},
pages = {32--44},
doi = {10.65591/ces-187-2026}
}
EUVIMED